Skip to main content Accessibility help
×
Home
Hostname: page-component-59b7f5684b-7j4dq Total loading time: 5.738 Render date: 2022-10-02T04:37:54.248Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

References

Published online by Cambridge University Press:  19 October 2021

Joseph F. Goldberg
Affiliation:
Icahn School of Medicine at Mount Sinai, New York
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Psychopharmacology
Translating Findings From Evidence-Based Trials into Real-World Clinical Practice
, pp. 508 - 567
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adamson, SJ, Sellman, JD, Foulds, JA, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2015; 35: 143149CrossRefGoogle ScholarPubMed
Adan-Manes, J, Novalbos, J, López-Rodríguez, R, et al. Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther 2006; 31: 397400CrossRefGoogle ScholarPubMed
Adler, LA, Dirks, B, Deas, PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74: 694702CrossRefGoogle ScholarPubMed
Afshar, M, Knapp, CM, Sarid-Segal, O, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse 2012; 38: 181186CrossRefGoogle ScholarPubMed
Agabio, R, Trogu, E, Pani, PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev 2018; 4: CD008581Google ScholarPubMed
Agarwal, LJ, Berger, CE, Gill, L. Naltrexone for severe self-harm: a case report. Am J Psychiatry 2011; 168: 437438CrossRefGoogle ScholarPubMed
Agid, O, Siu, CO, Potkin, SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry 2013; 170: 13351344CrossRefGoogle ScholarPubMed
Aguglia, A, Mineo, L, Rodolico, A, et al. Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study. Int Clin Psychopharmacol 2018; 33: 121–130CrossRefGoogle Scholar
Ahmed, AO, Richardson, J, Buckner, A, et al. Do cognitive deficits predict negative emotionality and aggression in schizophrenia? Psychiatry Res 2018a; 259: 350357CrossRefGoogle Scholar
Ahmed, R, Kotapati, VP, Khan, AM, et al. Adding psychotherapy to the naltrexone treatment of alcohol use disorder: a meta-analytic review. Cureus 2018b; 10: e3107Google ScholarPubMed
Aiken, CB, Orr, C. Rechallenge with lamotrigine after a rash. Psychiatry (Edgmont) 2010; 7: 2732Google ScholarPubMed
Airagnes, G, Lemogne, C, Renuy, A, et al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCS cohort. BMC Public Health 2019; 19: 566CrossRefGoogle ScholarPubMed
Albers, LJ, Ozdemir, V, Marder, SR. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose adjusted drug interaction strategy. J Clin Psychopharmacol 2005; 25: 170174CrossRefGoogle ScholarPubMed
Albertini, E, Ernst, CL, Tamaroff, RS. Psychopharmacological decision making in bipolar disorder during pregnancy and lactation: a case-by-case approach to using current evidence. Focus 2019; 17: 249258CrossRefGoogle ScholarPubMed
Albott, CS, Lim, KO, Forbes, MK, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 2018; 79: 17m11684CrossRefGoogle ScholarPubMed
Alexopoulos, GS, Canuso, CM, Gharabawi, GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008; 16: 2130CrossRefGoogle ScholarPubMed
Alexopoulos, GS, Katz, IR, Reynolds, CF 3rd, et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med 2001; Spec No Pharmacotherapy: 186Google Scholar
Allan, ER, Alpert, M, Sison, CE, et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 1996; 57: 455459CrossRefGoogle ScholarPubMed
Allen, MH, Hirschfeld, RM, Wozniak, PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272275CrossRefGoogle ScholarPubMed
Allgulander, C, Mangano, R, Zhang, J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387396CrossRefGoogle ScholarPubMed
Alpert, M, Allan, ER, Citrome, L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26: 367371Google ScholarPubMed
Alphs, L, Davis, JM. Noncatecholaminergic treatments of tardive dyskinesia. J Clin Psychopharmachol 1982; 2: 380385Google ScholarPubMed
Altemus, M, Neeb, CC, Davis, A, et al. Phenotypic differences between pregnancy-onset and postpartum-onset major depressive disorder. J Clin Psychiatry 2012; 73: e1485e1491CrossRefGoogle ScholarPubMed
Altshuler, LL, Bauer, M, Frye, MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response?: a review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 16171622CrossRefGoogle ScholarPubMed
Altshuler, LL, Post, RM, Hellemann, G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009; 70: 450457CrossRefGoogle ScholarPubMed
Altshuler, L, Suppes, T, Black, D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 12521262CrossRefGoogle ScholarPubMed
Altshuler, LL, Suppes, T, Black, DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163: 313315CrossRefGoogle ScholarPubMed
Alvarez, E, Perez, V, Dragheim, M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15: 589600CrossRefGoogle ScholarPubMed
American Psychiatric Association. Practice Guideline for the Treatment of Major Depressive Disorder, 3rd Edn. Arlington, VA: American Psychiatric Association; 2010Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. Arlington, VA: American Psychiatric Association; 2013Google Scholar
American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. Am J Hosp Pharm. 1993; 50: 17201723Google Scholar
Amerio, A, Ossola, P, Scagnelli, F, et al. Safety and efficacy of lithium in children and adolescents: a systematic review in bipolar illness. Eur Psychiatry 2018; 54: 8597CrossRefGoogle ScholarPubMed
Amerio, A, Stubbs, B, Odone, A, et al. The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review and meta-analysis. J Affect Disord 2015; 186: 99109CrossRefGoogle ScholarPubMed
Amieva, H, LeGoff, M, Millet, X, et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492498CrossRefGoogle ScholarPubMed
Amital, D, Vishne, T, Roitman, S, et al. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 836837CrossRefGoogle ScholarPubMed
Amsterdam, JD, Berwish, NJ. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 1989; 22: 2125CrossRefGoogle ScholarPubMed
Amsterdam, JD, Fawcett, J, Quitkin, FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997; 154: 963969Google ScholarPubMed
Amsterdam, JD, Li, Y, Soeller, I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol 2009; 29: 378382CrossRefGoogle ScholarPubMed
Anand, A, Charney, DS, Oren, DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 170176CrossRefGoogle ScholarPubMed
Anderson, M, Björkhem-Bergman, L, Beck, O. Possible mechanism for inhibition of morphine formation from 6-acetylmorphine after intake of street heroin. Forensic Sci Int 2015; 252: 150156CrossRefGoogle Scholar
Andrade, C. Nonsteroidal anti-inflammatory drugs and 5-HT3 serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J Clin Psychiatry 2014; 75: e707e709CrossRefGoogle Scholar
Andrade, C. Antidepressant exposure during pregnancy and risk of autism in the offspring: 1: meta-review of meta-analyses. J Clin Psychiatry 2017; 78: e1047e1051CrossRefGoogle ScholarPubMed
Andrade, C, Kisely, S, Monteiro, I, et al. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatry Res 2015; 60: 1421CrossRefGoogle ScholarPubMed
Andrade, C, Sandarsh, S, Chetan, KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 15651575CrossRefGoogle Scholar
Andreason, NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39: 784788CrossRefGoogle Scholar
Andreason, NC, Liu, D, Ziebell, S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170: 609615CrossRefGoogle Scholar
Andreason, NC, Pressler, M, Nopoulos, P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255262CrossRefGoogle Scholar
Andrezina, R, Josiassen, RC, Marcus, RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison of intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188: 281292CrossRefGoogle ScholarPubMed
Anglin, RES, Samaan, Z, Walter, SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry 2013; 202: 100107CrossRefGoogle ScholarPubMed
Anton, RF, Moak, DH, Latham, PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53: 225231. Erratum in: Arch Gen Psychiatry 1996; 53: 576CrossRefGoogle ScholarPubMed
Anton, RF, Myrick, H, Wright, TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011; 168: 709717CrossRefGoogle ScholarPubMed
Anton, RF, O’Malley, SS, Ciraulo, DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. J Am Med Assoc 2006; 295: 20032017CrossRefGoogle ScholarPubMed
Anttila, S, Viikki, M, Huuhka, K, et al. TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. Neurosci Lett 2009; 464: 4346CrossRefGoogle ScholarPubMed
Appelberg, BG, Syvälahti, EK, Koskinen, TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448452CrossRefGoogle ScholarPubMed
Appelhof, BC, Fliers, E, Wekking, EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90: 26662674CrossRefGoogle ScholarPubMed
Arato, M, O’Connor, R, Meltzer, HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207215CrossRefGoogle ScholarPubMed
Argolo, FC, Cavalcanti-Ribeiro, P, Netto, LR, et al. Prevention of posttraumatic stress disorder with propranolol: a meta-analytic review. J Psychosom Res 2015; 79: 8993CrossRefGoogle ScholarPubMed
Argyropoulou, P, Patakas, D, Koukou, A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 214220CrossRefGoogle ScholarPubMed
Arnold, LE. Methylphenidate vs. amphetamine: comparative review. J Attention Disord 2000; 4: 200211CrossRefGoogle Scholar
Arnold, LM, Mutasim, DF, Dwight, MM, et al. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol 1999; 19: 1518CrossRefGoogle ScholarPubMed
Arnow, BA, Blasey, C, Williams, LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry 2015; 172: 743750CrossRefGoogle ScholarPubMed
Arns, M, Bruder, G, Hegerl, U, et al. EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study. Clin Neurophysiol 2016; 17: 509519CrossRefGoogle Scholar
Arntz, A, Van den Hoorn, M, Cornelis, J. Reliability and validity of the borderline personality disorder severity index. J Pers Disord 2003; 17: 4559CrossRefGoogle ScholarPubMed
Aronson, R, Offman, HJ, Joffe, RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53: 842848CrossRefGoogle ScholarPubMed
Askari, N, Moin, M, Sanati, M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2012; 26: 883892CrossRefGoogle ScholarPubMed
Astill Wright, L, Sijbrandij, M, Sinnerton, R, et al. Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Transl Psychiatry 2019; 9: 334CrossRefGoogle ScholarPubMed
AstraZeneca. A multi-center, double-blind, randomized-withdrawal, parallel-group, placebo-controlled Phase III study of the efficacy and safety of quetiapine fumarate extended release (Seroquel XR) as monotherapy in the maintenance treatment of patients with major depressive disorder following an open-label stabilization period (AMETHYST study). www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/8579609 ClinicalTrials.gov ID NCT00278941. Study code: D1448C00005. 2008Google Scholar
Astrup, A, Caterson, I, Zelissen, P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 16581669CrossRefGoogle ScholarPubMed
Avgerinos, KI, Spyrou, N, Bougioukas, KI, et al. Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Exp Gerontol 2018; 108: 166173CrossRefGoogle ScholarPubMed
Awortwe, C, Makiwane, M, Reuter, H, et l. Critical evaluation of causality assessment of herb-drug interactions in patients. Br J Clin Pharmacol 2018; 84: 679693CrossRefGoogle ScholarPubMed
Azuma, K, Takaesu, Y, Soeda, H, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg 2018; 5: 362368CrossRefGoogle ScholarPubMed
Baandrup, L, Ebdrup, BH, Rasmussen, , et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev 2018; 3: CD011481Google ScholarPubMed
Babor, TF, Hofmann, M, DelBoca, FK, et al. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599608CrossRefGoogle ScholarPubMed
Bacaltchuk, J, Hay, P, Mari, JJ. Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust N Z J Psychiatry 2000; 34: 310317CrossRefGoogle ScholarPubMed
Back, SE, McCauley, JL, Korte, KJ, et al. A double-blind, randomized, controlled pilot study of N-acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry 2016; 77: e1439e1446CrossRefGoogle ScholarPubMed
Bagby, RM, Ryder, AG, Cristi, C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002; 27: 250257Google ScholarPubMed
Bahji, A, Forsyth, A, Groll, D, et al. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2020; 96: 109735CrossRefGoogle ScholarPubMed
Baillon, SF, Narayana, U, Luxenberg, JS, et al. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2018; 10: CD003945Google ScholarPubMed
Bak, M, Weltens, I, Bervoets, C, et al. The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis. Eur Psychiatry 2019; 57: 78100CrossRefGoogle ScholarPubMed
Baker, RW, Kinon, BJ, Maguire, GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342348CrossRefGoogle ScholarPubMed
BALANCE Investigators and Collaborators; Geddes, JR, Goodwin, GM, Rendell, J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385395Google ScholarPubMed
Baldaçara, L, Cogo-Moreira, H, Parreira, BL, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2016; 77: 398406CrossRefGoogle ScholarPubMed
Baldessarini, RJ, Vázques, G, Tondo, L. Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011; 80: 131135CrossRefGoogle ScholarPubMed
Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012; 22: 482491CrossRefGoogle Scholar
Bali, V, Chatterjee, S, Carnahan, RM, et al. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv 2015; 66: 13331340CrossRefGoogle ScholarPubMed
Ballenger, JC, Davidson, JR, Lecrubier, Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59(Suppl 8): 4754Google Scholar
Bandelow, B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995; 2: 7381CrossRefGoogle Scholar
Baniasadi, M, Hosseini, G, Bordbar, MRF, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract 2014; 20: 419427CrossRefGoogle ScholarPubMed
Banzi, R, Cusi, C, Randazzo, C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev 2015; 4: CD002919Google ScholarPubMed
Barbee, JG, Thompson, TR, Jamhour, NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72: 14051412CrossRefGoogle ScholarPubMed
Bareggi, SR, Bianchi, L, Cavallaro, R, et al. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004; 18: 329335CrossRefGoogle ScholarPubMed
Barker, MJ, Greenwood, KM, Jackson, M, et al. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 3748CrossRefGoogle ScholarPubMed
Barnett, R, Maruff, P, Vance, A, et al. Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. Psychol Med 2001; 31: 11071115CrossRefGoogle ScholarPubMed
Barnett, SD, Kramer, ML, Casat, CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365368CrossRefGoogle ScholarPubMed
Barrons, R, Roberts, N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther 2010; 35: 153167CrossRefGoogle ScholarPubMed
Barsky, AJ, Saintfort, R, Rogers, MP, et al. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc 2002; 287: 622627CrossRefGoogle ScholarPubMed
Batail, JM, Langrée, B, Robert, G, et al. Use of very-high dose olanzapine in treatment-resistant schizophrenia. Schizophr Res 2014; 159: 411414CrossRefGoogle ScholarPubMed
Batelaan, NM, Bosman, RC, Muntingh, A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. Br Med J 2017; 358: j3927CrossRefGoogle ScholarPubMed
Bauer, M, Dell’Osso, L, Kasper, S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013; 151: 209219CrossRefGoogle ScholarPubMed
Bauer, MS, Whybrow, PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435440CrossRefGoogle ScholarPubMed
Baune, BT, Brignone, M, Larsen, KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol 2018; 21: 97107CrossRefGoogle ScholarPubMed
Bazire, SR. Sudden death associated with switching monoamine oxidase inhibitors. Drug Intell Clin Pharm 1986; 20: 954956CrossRefGoogle ScholarPubMed
Beasley, CM Jr, Tollefson, G, Tran, P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111123CrossRefGoogle ScholarPubMed
Beck, AT, Epstein, N, Brown, G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893897CrossRefGoogle ScholarPubMed
Begemann, MJ, Dekker, CF, van Lunenburg, M, et al. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012; 141: 179184CrossRefGoogle ScholarPubMed
Beinat, C, Banister, SD, Herrera, M, et al. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs 2015; 29: 529542CrossRefGoogle ScholarPubMed
Bellatuono, C, Tofani, S, Di Sciascio, G, et al. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013; 35: 38CrossRefGoogle Scholar
Bellino, S, Paradiso, E, Bogetto, F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 11111115CrossRefGoogle ScholarPubMed
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006; 67: 10421046CrossRefGoogle ScholarPubMed
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res 2008; 161: 206212CrossRefGoogle ScholarPubMed
Bellino, S, Bozzatello, P, Rinaldi, C, et al. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat 2011; 2011: 680194Google ScholarPubMed
Bellino, S, Bozzatello, P, Rocca, G, et al. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 2014; 28: 125132CrossRefGoogle ScholarPubMed
Bellino, S, Paradiso, E, Bozzatello, P, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol 2010; 24: 333339CrossRefGoogle ScholarPubMed
Benazzi, F. Characteristics of bipolar II patients with interpersonal rejection sensitivity. Psychiatr Clin Neurosci 2001; 54: 499501CrossRefGoogle Scholar
Bergamaschi, MM, Queiroz, RH, Chagas, MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36: 12191226CrossRefGoogle ScholarPubMed
Bergero-Miguel, T, García-Encinas, MA, Villena-Jimena, A, et al. Gender dysphoria and social anxiety: an exploratory study in Spain. J Sex Med 2016; 13: 12701278CrossRefGoogle ScholarPubMed
Beri, A, Boydell, J. Clozapine in borderline personality disorder: a review of the evidence. Ann Clin Psychiatry 2014; 26: 139144Google Scholar
Berk, M, Dean, OM, Cotton, SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75: 628636CrossRefGoogle ScholarPubMed
Berlant, J. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004; 4: 24CrossRefGoogle ScholarPubMed
Berlant, J, van Kammen, DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63: 1520CrossRefGoogle ScholarPubMed
Berlin, HA, Koran, LM, Jenike, MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72: 716721CrossRefGoogle ScholarPubMed
Berman, M, Marcus, RN, Swanink, R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843853CrossRefGoogle ScholarPubMed
Berman, RM, Fava, M, Thase, ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197206CrossRefGoogle Scholar
Bersudsky, Y. Phenytoin: an anti-bipolar anticonvulsant? Int J Neuropsychopharmacol 2006; 9: 479484CrossRefGoogle ScholarPubMed
Berwaerts, J, Lane, R, Nuamah, IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011; 129: 252260CrossRefGoogle ScholarPubMed
Berwaerts, J, Melkote, R, Nuamah, I, et al. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012b; 138: 247258CrossRefGoogle ScholarPubMed
Berwaerts, J, Xu, H, Nuamah, I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012a; 136: e51e60CrossRefGoogle ScholarPubMed
Beucke, JC, Sepulcre, J, Talukdar, T, et al. Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry 2013; 70: 619629CrossRefGoogle ScholarPubMed
Bhatara, VS, Magnus, RD, Paul, KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32: 432436CrossRefGoogle ScholarPubMed
Biederman, J, Faraone, SV, Keenan, K, et al. Evidence of familial association between attention deficit disorder and major affective disorders. Arch Gen Psychiatry 1991a; 48: 633642CrossRefGoogle ScholarPubMed
Biederman, J, Faraone, SV, Keenan, K, et al. Familial association between attention deficit disorder and anxiety disorders. Am J Psychiatry 1991b; 148: 251256Google ScholarPubMed
Biederman, J, Fried, R, Tarko, L, et al. Memantine in the treatment of executive function deficits in adults with ADHD. J Atten Disord 2017; 21: 343352CrossRefGoogle ScholarPubMed
Biederman, J, Joshi, G, Mick, E, et al. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 2010; 16: 91102CrossRefGoogle ScholarPubMed
Biederman, J, Krishnan, S, Zhang, Y, et al. Efficacy and safety of lisdexamfetamine (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study. Clin Ther 2007; 29: 450463CrossRefGoogle Scholar
Biederman, J, Lindsten, A, Sluth, LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol 2019; 33: 511521CrossRefGoogle ScholarPubMed
Biederman, J, Petty, CR, Wilens, TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008a; 165: 107115CrossRefGoogle ScholarPubMed
Biederman, J, Seidman, LJ, Petty, CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008b; 69: 11501156CrossRefGoogle ScholarPubMed
Biel, MG, Peselow, E, Mulcare, L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord 2007; 9: 435442CrossRefGoogle ScholarPubMed
Bighelli, I, Castellazzi, M, Cipriani, A, et al. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2018; 4: CD010676Google ScholarPubMed
Bilder, RM, Goldman, RS, Volavka, J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 10181028CrossRefGoogle ScholarPubMed
Binder, RL, Levy, R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138: 12431244Google ScholarPubMed
Birkeland, SF. Psychopharmacological treatment and course in paranoid personality disorder: a case series. Int Clin Psychopharmacol 2013; 28: 283285CrossRefGoogle ScholarPubMed
Birks, JS, Harvey, RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2018; (6): CD001190Google Scholar
Birmingham, CL, Goldner, EM, Bakan, R, et al. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994; 15: 231235Google ScholarPubMed
Bisaga, A, Aharonovich, E, Garawi, F, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 81: 267274CrossRefGoogle ScholarPubMed
Bishara, D, Olofinjana, O, Sparshatt, A, et al: Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33: 329335CrossRefGoogle ScholarPubMed
Bishop, JR, Moline, J, Ellingrod, VL, et al. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006; 31: 22812288CrossRefGoogle Scholar
Bisol, LW, Lara, DR. Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments. J Psychopharmacol 2001; 24: 421424CrossRefGoogle Scholar
Bivard, A, Lillicrap, T, Krishnamurthy, V, et al. MIDAS (Modafinil in Debilitating Fatigue After Stroke): a randomized, double-blind, placebo-controlled, cross-over trial. Stroke 2017; 48: 12931298CrossRefGoogle ScholarPubMed
Bixby, AL, VandenBerg, A, Bostwick, JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother 2019; 53: 186194CrossRefGoogle ScholarPubMed
Black, DW, Gabel, J, Hansen, J, et al. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000; 12: 205211CrossRefGoogle ScholarPubMed
Black, N, Stockings, E, Campbell, G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6: 9951010CrossRefGoogle ScholarPubMed
Blackford, JU, Buckholtz, JW, Avery, SN, et al. A unique role for the human amygdala in novelty detection. Neuroimage 2010; 50: 11881193CrossRefGoogle ScholarPubMed
Blanchard, EB, Jones-Alexander, J, Buckley, TC, et al. Psychometric properties of the PTSD checklist (PCL). Behav Res Ther 1996; 34: 699673CrossRefGoogle Scholar
Blessing, EM, Steenkamp, MM, Manzanares, J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 2015; 12: 825836CrossRefGoogle ScholarPubMed
Blier, P, Bergeron, R, de Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997; 16: 333338CrossRefGoogle ScholarPubMed
Blier, P, Ward, HE, Tremblay, P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281288CrossRefGoogle ScholarPubMed
Bloch, M, Schmidt, PJ, Danaceau, MA, et al. Dehydroandrosterone treatment of mid-life dysthymia. Biol Psychiatry 1999; 45: 15331541CrossRefGoogle ScholarPubMed
Bloch, MH, Landeros-Weisenberger, A, Dombrowski, P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 2007; 62: 839846CrossRefGoogle ScholarPubMed
Bloch, MR, Elliott, M, Thompson, H, et al. Fluoxetine in pathological skin-picking: open-label and double-blind results. Psychosomatics 2001; 42: 314319CrossRefGoogle Scholar
Blodgett, JC, Del Re, AC, Maisel, NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 2014; 38: 14811488CrossRefGoogle ScholarPubMed
Blom, TJ, Mingione, CJ, Guerdjikova, AI, et al. Placebo response in binge eating disorder: a pooled analysis of 10 clinical trials from one research group. Eur Eat Disord Rev 2014; 22: 140146CrossRefGoogle ScholarPubMed
Bocchetta, A, Ardau, R, Fanni, T, et al. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Med 2015; 13: 12CrossRefGoogle ScholarPubMed
Boeker, T. Ziprasidone and migraine headache. Am J Psychiatry 2002; 159: 14351436CrossRefGoogle ScholarPubMed
Bogenschutz, MP, Nurnberg, GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104109CrossRefGoogle ScholarPubMed
Boggs, DL, Kelly, DL, Feldman, S, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res 2008; 101: 347348CrossRefGoogle ScholarPubMed
Bohus, MJ, Landwehrmeyer, GB, Stiglmayr, CE, et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999; 60: 598603CrossRefGoogle Scholar
Bonari, L, Pinto, N, Ahn, E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 726735CrossRefGoogle ScholarPubMed
Bondolfi, G, Chautems, C, Rochat, B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl) 1996; 128: 421425CrossRefGoogle ScholarPubMed
Bondolfi, G, Lissner, C, Kosel, M, et al. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 2000; 3: 5560CrossRefGoogle ScholarPubMed
Bonn-Miller, MO, Loflin, MJE, Thomas, BF, et al. Labeling accuracy of cannabidiol extracts sold online. J Am Med Assoc 2017; 218: 17081709CrossRefGoogle Scholar
Boonstra, E, de Kleijn, R, Colzato, LS, et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol 2015; 6: 1520CrossRefGoogle ScholarPubMed
Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158169CrossRefGoogle Scholar
Borras, L, Huguelet, P, Eytan, A. Delusional “pseudotranssexualism” in schizophrenia. Psychiatry 2007; 70: 175179CrossRefGoogle Scholar
Bortnick, B, El-Khalili, N, Banov, M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128: 8394CrossRefGoogle Scholar
Bose, A, Li, D, Gandhi, C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008; 16: 1420CrossRefGoogle ScholarPubMed
Bottlender, R, Rudolf, D, Strauß, A, et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63: 7983CrossRefGoogle ScholarPubMed
Boulenger, J-P, Loft, H, Florea, I. A randomized clinical study of LuAA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26: 14081416CrossRefGoogle ScholarPubMed
Boulenger, J-P, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29: 138149CrossRefGoogle ScholarPubMed
Bourgeois, JA. The management of performance anxiety with beta adrenergic-blocking agents. Jefferson J Psychiatry 1991; 9: 1328CrossRefGoogle Scholar
Bourgeois, BF, D’Souza, J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav 2005; 7: 375382CrossRefGoogle ScholarPubMed
Bowden, CL, Calabrese, JR, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392400CrossRefGoogle ScholarPubMed
Bowden, CL, Janicak, PG, Orsulak, P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765770Google ScholarPubMed
Bowden, CL, Keck, PE Jr., McElroy, SL, et al. A randomized, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481489CrossRefGoogle ScholarPubMed
Bowden, CL, Singh, R, Weisler, P, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 2012; 126: 342350CrossRefGoogle ScholarPubMed
Bowden, CL, Vieta, E, Ice, KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130137CrossRefGoogle Scholar
Bowtell, M, Eaton, S, Thien, K, et al. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res 2018; 195: 231236CrossRefGoogle ScholarPubMed
Bozzatello, P, Rocca, P, Uscinska, M, et al. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs 2017; 31: 809819CrossRefGoogle ScholarPubMed
Brady, K, Pearlstein, T, Asnis, G, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. J Am Med Assoc 2000; 283: 1837–1844CrossRefGoogle ScholarPubMed
Braun, P, Greenberg, S, Dasberg, H, et al. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236238Google ScholarPubMed
Brawman-Mintzer, O, Knapp, RG, Nietert, PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 13211325CrossRefGoogle ScholarPubMed
Breier, A, Buchanan, RW, Kirkpatrick, B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 2060Google ScholarPubMed
Breilmann, J, Girlanda, F, Guaiana, G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2019; (3): CD010677Google ScholarPubMed
Breitbart, W, Rosenfeld, B, Kaim, M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161: 411420CrossRefGoogle ScholarPubMed
Brekhman, II, Dardymov, IV. New substances of plant origin which increase nonspecific resistance. Ann Rev Pharmacol 1969; 9: 419430CrossRefGoogle ScholarPubMed
Bremner, JD, Shearer, K, McCaffery, P. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry 2012; 73: 3750CrossRefGoogle ScholarPubMed
Briggs-Gowan, MJ, Carter, S, Bosson-Heenan, J, et al. Are infant-toddler social-emotional and behavioral problems transient? J Am Acad Child Adolesc Psychiatry 2006; 45: 849858CrossRefGoogle ScholarPubMed
Britnell, SR, Jackson, AD, Brown, JN., et al. Aripiprazole for post-traumatic stress disorder: a systematic review. Clin Neuropharmacol 2017; 40: 273278CrossRefGoogle ScholarPubMed
Bro, SP, Kjaersgard, MI, Parner, ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol 2015; 7: 139147CrossRefGoogle ScholarPubMed
Brown, WA. Placebo as a treatment for depression. Neuropsychopharmacology 1994; 10: 265269CrossRefGoogle ScholarPubMed
Brown, ES, Gabrielson, B. A randomized double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord 2012; 143: 257260CrossRefGoogle ScholarPubMed
Brown, ES, Gorman, AR, Hynan, LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007; 27: 498502CrossRefGoogle ScholarPubMed
Brown, ES, Todd, JP, Hu, T, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 2015; 172: 10141021CrossRefGoogle ScholarPubMed
Bruder, GE, Sedoruk, JP, Stewart, JW, et al. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry 2008; 63: 11711177CrossRefGoogle ScholarPubMed
Brunet, A, Saumier, D, Liu, A, et al. Reduction of PTSD symptoms with pre-reactivation propranolol therapy: randomized controlled trial. Am J Psychiatry 2018; 175: 427433CrossRefGoogle ScholarPubMed
Brunner, E, Tohen, M, Osuntokun, O, et al. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014; 39: 25492559CrossRefGoogle ScholarPubMed
Bruno, A, Micò, U, Pandolfo, G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012; 26: 14561462CrossRefGoogle ScholarPubMed
Buchanan, RW, Breier, A, Kirkpatrick, B, et al. Positive and negative symptoms response to clozapine with and without the deficit syndrome. Am J Psychiatry 1998; 155: 751760Google ScholarPubMed
Bugarski-Kirola, D, Iwata, N, Sameliak, S, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry 2016; 3: 11151128CrossRefGoogle ScholarPubMed
Buitelaar, JK, Sobanski, E, Stieglitz, RD, et al. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry 2012; 73: 10971102CrossRefGoogle ScholarPubMed
Burdick, KE, Endick, CJ, Goldberg, JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res 2005; 136: 4350CrossRefGoogle ScholarPubMed
Burdick, KE, Braga, RJ, Nnadi, CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 2012; 73: 103112CrossRefGoogle ScholarPubMed
Burdick, KE, Russo, M, Frangou, S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med 2014; 44: 30833096CrossRefGoogle ScholarPubMed
Bürkner, PC, Williams, DR, Simmons, TC, et al. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophr Bull 2017; 43: 12911303CrossRefGoogle ScholarPubMed
Butterfield, MI, Becker, ME, Connor, KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001; 16: 197203CrossRefGoogle ScholarPubMed
Bystritsky, A, Kerwin, L, Feusner, JD, et al. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull 2008; 41: 4651Google ScholarPubMed
Cain, JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a “therapeutic window”? J Clin Psychiatry 1992; 53: 272277Google ScholarPubMed
Cakir, S, Kulakisizoglu, IB. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat 2008; 4: 963966CrossRefGoogle ScholarPubMed
Calabrese, JR, Bowden, CL, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 10131024CrossRefGoogle ScholarPubMed
Calabrese, JR, Bowden, CL, Sachs, GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 7988CrossRefGoogle ScholarPubMed
Calabrese, JR, Keck, PE Jr, Starace, A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2015; 76: 284292CrossRefGoogle ScholarPubMed
Calabrese, JR, Pikalov, A, Streicher, C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017a; 27: 865876CrossRefGoogle ScholarPubMed
Calabrese, JR, Sanchez, R, Jin, N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 2017b; 78: 324331CrossRefGoogle ScholarPubMed
Calabrese, JR, Shelton, MD, Rapport, DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 21522161CrossRefGoogle ScholarPubMed
Calabrese, JR, Suppes, T, Bowden, CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder: Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841850CrossRefGoogle ScholarPubMed
Campbell, M, Adams, PB, Small, AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445453CrossRefGoogle ScholarPubMed
Campbell, M, Small, AM, Green, WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650656CrossRefGoogle ScholarPubMed
Canuso, CM, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175: 620630CrossRefGoogle ScholarPubMed
Carbon, H, Hsieh, CH, Kane, JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 2017; 78: e264e278CrossRefGoogle ScholarPubMed
Cardenas, D. Let not thy food be confused with thy medicine: the Hippocratic misquotation. E-SPEN 2013; 8: e260e262CrossRefGoogle Scholar
Careri, JM, Draine, AE, Hanover, R, et al. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord 2015; 17: 10.4088/PCC.15m01831Google ScholarPubMed
Carey, P, Suliman, S, Ganesan, K, et al. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012; 27: 386391CrossRefGoogle Scholar
Carhart-Harris, RL, Bolstridge, M, Dy, CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235: 399408CrossRefGoogle ScholarPubMed
Carman, J, Peuskens, S, Vangeneugden, A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207213CrossRefGoogle ScholarPubMed
Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Amer 1993; 77: 185202CrossRefGoogle ScholarPubMed
Carpenter, KM, Hasin, DS. Reliability and discriminant validity of the Type I/II and Type A/B alcoholic subtype classifications in untreated problem drinkers: a test of the Apollonian–Dionysian hypothesis. Drug Alcohol Depend 2001; 63: 5167CrossRefGoogle ScholarPubMed
Casamassima, F, Huang, J, Fava, M, et al. Phenotypic effects of bipolar liability gene among individuals with major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 303309Google ScholarPubMed
Casey, DE, Daniel, DG, Tamminga, C, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009; 34: 13301338CrossRefGoogle ScholarPubMed
Casey, DE, Daniel, DG, Wassef, AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 182192CrossRefGoogle ScholarPubMed
Castells, X, Blanco-Silvente, L, Cunill, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 8: CD007813Google ScholarPubMed
Castells, X, Cunill, R, Pérez-Mañá, C, et al. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2016; 9: CD007380Google ScholarPubMed
Castro, VM, Roberson, AM, McCoy, TH, et al. Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacology 2016; 41: 11381143CrossRefGoogle Scholar
Catalá-López, F, Hutton, B, Núñez-Beltrán, A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One 2017; 12: e0180355CrossRefGoogle ScholarPubMed
Caye, A, Rocha, TB, Anselmi, L, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry 2016; 73: 705712CrossRefGoogle ScholarPubMed
Center for Behavioral Health Statistics and Quality (CBHSQ). Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15–4927, NSDUH Series H-50. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015Google Scholar
Chakrabarti, A, Bagnall, A, Chue, P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007; (4): CD001943Google Scholar
Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006; 354: 579587CrossRefGoogle ScholarPubMed
Chan, GC, Hinds, TR, Impey, S, et al. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 1998; 18: 53225332CrossRefGoogle ScholarPubMed
Chang, K, Saxena, K, Howe, M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 298304CrossRefGoogle ScholarPubMed
Chang, HY, Tseng, PT, Stubbs, B, et al. The efficacy and tolerability of paliperidone in mania of bipolar disorder: a preliminary meta-analysis. Exp Clin Psychopharmacol 2017; 25: 422433CrossRefGoogle ScholarPubMed
Chang, SS, Liu, CM, Lin, SH, et al. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr Bull 2009; 35: 213221CrossRefGoogle ScholarPubMed
Charney, DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry 2004; 161: 195216CrossRefGoogle ScholarPubMed
Charney, DA, Heath, LM, Zikos, E, et al. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2015; 39: 17561765CrossRefGoogle ScholarPubMed
Chaudhry, IB, Neelam, K, Duddu, V, et al. Ethnicity and Psychopharmacology. J Psychopharmachol 2008; 22: 673680CrossRefGoogle ScholarPubMed
Chekroud, AM, Gueorguieva, R, Krumholz, HM, et al. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry 2017; 74: 370378CrossRefGoogle ScholarPubMed
Chen, JJ, Hua, H, Massihi, L, et al. Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism. J Psychiatry Clin Neurosci 2019a; 31: 188195Google ScholarPubMed
Chen, JX, Su, YA, Bian, QT, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130140CrossRefGoogle ScholarPubMed
Chen, MH, Lin, WC, Wu, HJ, et al. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 2019b; 251: 162169CrossRefGoogle Scholar
Chen, TR, Huang, HC, Hsu, JH, et al. Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res 2019c; 118: 7383CrossRefGoogle ScholarPubMed
Chen, YF, Wang, SJ, Khin, NA, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 2010; 9: 217229CrossRefGoogle ScholarPubMed
Chengappa, KNR, Brar, JS, Gannon, JM, Schlicht, PJ. Adjunctive use of a standardized extract of Withania somnifera (ashwaganda) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2018; 79: 17m11826CrossRefGoogle Scholar
Chengappa, KN, Bowie, CR, Schlicht, PJ, et al. Randomized placebo-controlled adjunctive study of an extract of Withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry 2013; 74: 10761083CrossRefGoogle ScholarPubMed
Chessick, CA, Allen, MH, Thase, M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; (3) :CD006115Google ScholarPubMed
Chiappini, S, Schifano, F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s “Suspected Adverse Drug Reactions” database. CNS Drugs 2016; 30: 647654CrossRefGoogle Scholar
Chick, J, Aschauer, H, Hornik, K, et al. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 2004; 74: 6170CrossRefGoogle ScholarPubMed
Cho, M, Lee, TY, Kwak, YB, et al. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry 2019; 53: 742759CrossRefGoogle ScholarPubMed
Chollet, F, Tardy, J, Albucher, JF. Fluoxetine for motor recovery after stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123130CrossRefGoogle ScholarPubMed
Choy, Y, Peselow, ED, Case, BG, et al. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr Psychiatry 2007; 48: 419425CrossRefGoogle ScholarPubMed
Christensen, J, Grønborg, TK, Sørensen, MJ. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. J Am Med Assoc 2013; 309: 16961703CrossRefGoogle ScholarPubMed
Christenson, GA, MacKenzie, TB, Mitchell, JE, et al. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 1991; 148: 15661571Google ScholarPubMed
Chung, YC, Lee, CR, Park, TW, et al. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry 2009; 10: 156162CrossRefGoogle Scholar
Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 13571366CrossRefGoogle ScholarPubMed
Citrome, L. The ABCs of dopamine receptor partial agonists – aripiprazole, brexpiprazole, and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015; 69: 12111220CrossRefGoogle Scholar
Citrome, L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 2017a; 37: 138147CrossRefGoogle ScholarPubMed
Citrome, L, Meng, X, Hochfeld, M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Research 2011; 131(1–3): 7581CrossRefGoogle ScholarPubMed
Citrome, L, Durgam, S, Lu, K, et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry 2016a; 77: 109115CrossRefGoogle ScholarPubMed
Citrome, L, Ota, A, Nagamizu, K, et al. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol 2016b; 31: 192201CrossRefGoogle ScholarPubMed
Citrome, L, Landbloom, R, Chang, CT, et al. Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatr Dis Res 2017b; 13: 29552963CrossRefGoogle ScholarPubMed
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52: 15101514CrossRefGoogle ScholarPubMed
Ciudad, A, Alvarez, E, Roca, M, et al. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study. J Clin Psychiatry 2012; 73: 185191CrossRefGoogle Scholar
Claes, L, Bouman, WP, Witcomb, G, et al. Non-suicidal self-injury in trans people: associations with psychological symptoms, victimization, interpersonal functioning, and perceived social support. J Sex Med 2015; 12: 168179CrossRefGoogle ScholarPubMed
Clark, CT, Klein, AM, Perel, JM, et al. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 2013; 170: 12401247CrossRefGoogle ScholarPubMed
Clark, RD, Canive, JM, Calais, LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999; 12: 395401CrossRefGoogle ScholarPubMed
Clayton, AH, Stewart, RS, Fayyad, R, et al. Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. Arch Womens Ment Health 2006; 9: 151157CrossRefGoogle ScholarPubMed
Clemons, WE, Makela, E, Young, J. Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. Sleep Med 2004; 5: 509511CrossRefGoogle Scholar
Cloninger, CR. The Temperament and Character Inventory (TCI): A Guide to its Development and Use. St. Louis, MO: Washington University; Center for Psychobiology of Personality; 1994Google Scholar
Cloninger, CR, Przybeck, TR, Svrakic, DM. The Tridimensional Personality Questionnaire: US normative data. Psychol Rep 1991; 69: 10471057CrossRefGoogle Scholar
Cloninger, CR, Zohar, AH, Hirschmann, S, et al. The psychological costs and benefits of being highly persistent: personality profiles distinguish mood disorders from anxiety disorders. J Affect Disord 2012; 136: 758766CrossRefGoogle ScholarPubMed
Clyde, PW, Harari, AE, Getka, EJ, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. J Am Med Assoc 2003; 290: 29522958CrossRefGoogle ScholarPubMed
Coccaro, EF, Kavoussi, RJ. Fluoxetine and impulsive aggressive behavior in personality disordered subjects. Arch Gen Psychiatry 1997; 54: 10811088CrossRefGoogle ScholarPubMed
Coccaro, EF, Lee, RJ, Kavoussi, JR. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70: 653662CrossRefGoogle ScholarPubMed
Coccaro, EF, Adan, F, Allen, D, et al. Plasma-serum differences in the assessment of tricyclic antidepressant blood levels. Int Clin Psychopharmacol 1987; 2: 217224CrossRefGoogle ScholarPubMed
Cohen, JM, Hernández-Díaz, S, Bateman, BT, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol 2017; 130: 11921201CrossRefGoogle ScholarPubMed
Cohen, JM, Huybrechts, KF, Patorno, E, et al. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psychiatry 2019; 80: 18m12572CrossRefGoogle ScholarPubMed
Cohen, LG, Chesly, S, Eugenio, S, et al. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996; 156: 675677CrossRefGoogle ScholarPubMed
Cohen, LS, Soares, CN, Poitras, JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003; 160: 15191522CrossRefGoogle ScholarPubMed
Cohen, LS, Viguera, AC, McInerney, KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 2016; 173: 263270CrossRefGoogle ScholarPubMed
Cohen, NL, Ross, EC, Bagby, RM, et al. The 5-factor model of personality and antidepressant medication compliance. Can J Psychiatry 2004; 49: 106113CrossRefGoogle ScholarPubMed
Cole, JD, Kazarian, SS. The Level of Expressed Emotion Scale: a new measure of expressed emotion. J Clin Psychol 1988; 44: 3923973.0.CO;2-3>CrossRefGoogle ScholarPubMed
Comer, JS, Olfson, M, Mojtabai, R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 2010; 49: 10011010CrossRefGoogle ScholarPubMed
Compton, WM, Han, B, Blanco, C, et al. Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry 2018; 175: 741755CrossRefGoogle ScholarPubMed
Conley, RR, Kelly, DL, Richardson, CM, et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 2003; 23: 668671CrossRefGoogle ScholarPubMed
Connor, DF, Fletcher, KE, Swanson, JM, et al. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 15511559CrossRefGoogle ScholarPubMed
Connor, KM, Davidson, JRT, Churchill, LE, et al. Psychometric properties of the Social Phobia Inventory. Br J Psychiatry 2000; 176: 379386CrossRefGoogle ScholarPubMed
Connor, KM, Davidson, JR, Weisler, RH, et al. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006; 184: 2125CrossRefGoogle ScholarPubMed
Connor, KM, Hidalgo, RB, Crockett, B, et al. Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 337345CrossRefGoogle ScholarPubMed
Conus, P, Cotton, SM, Francey, SM, et al. Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. Schizophr Res 2017; 185: 130136CrossRefGoogle ScholarPubMed
Cook, IA, Hunter, AM, Gilmer, WS, et al. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) trial. J Clin Psychiatry 2013; 74: 5156CrossRefGoogle ScholarPubMed
Cools, R, Robbins, TW. Chemistry of the adaptive mind. Philos Trans A Math Phys Eng Sci 2004; 362: 28712888CrossRefGoogle ScholarPubMed
Cooper, TB, Bergner, PE, Simpson, GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry 1973; 130: 601603CrossRefGoogle ScholarPubMed
Cooper-Karaz, R, Apter, JT, Cohen, R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679688CrossRefGoogle Scholar
Corá-Locatelli, G, Greenberg, BD, Martin, J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59: 480481CrossRefGoogle ScholarPubMed
Cordás, TA, Tavares, H, Calderoni, DM, et al. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9: 769771CrossRefGoogle ScholarPubMed
Cornelius, JR, Salloum, IM, Ehler, JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700705CrossRefGoogle ScholarPubMed
Cornelius, JR, Salloum, IM, Thase, ME, et al. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 1998; 34: 117121Google ScholarPubMed
Cornelius, JR, Soloff, PH, George, A, et al. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull 1993; 29: 333337Google ScholarPubMed
Correll, CU, Kane, JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17: 647656CrossRefGoogle ScholarPubMed
Correll, CU, Davis, RE, Weingart, M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized trial. JAMA Psychiatry 2020; 77: 349358CrossRefGoogle Scholar
Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414425CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Kane, JM. What is the risk-benefit ratio of long-term antipsychotic treatment in patients with schizophrenia? World Psychiatry 2018; 17: 149160CrossRefGoogle Scholar
Correll, CU, Manu, P, Olshanskiy, V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009; 302: 17651773CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74: 675684CrossRefGoogle ScholarPubMed
Correll, CU, Skuban, A, Hobart, M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016; 174: 8292CrossRefGoogle ScholarPubMed
Cortese, S, Adamo, N, Del Giovane, C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727738CrossRefGoogle ScholarPubMed
Corya, SA, Williamson, D, Sanger, TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364372CrossRefGoogle ScholarPubMed
Coryell, W, Winokur, G, Solomon, D, et al. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997; 27: 281289CrossRefGoogle Scholar
Costi, S, Soleimani, L, Glasgow, A, et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacol 2019; 44: 18121819CrossRefGoogle ScholarPubMed
Coupland, CAC, Hill, T, Dening, T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 2019; 179: 10841093CrossRefGoogle ScholarPubMed
Cowdry, RW, Gardner, DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111119CrossRefGoogle ScholarPubMed
Crawford, MJ, Sanatinia, R, Barrett, B, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 2018; 175: 756764CrossRefGoogle ScholarPubMed
Crippa, JA, Derenusson, GN, Ferrari, TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25: 121130CrossRefGoogle ScholarPubMed
Cristancho, P, Lenze, EJ, Dixon, D, et al. Executive function predicts antidepressant treatment noncompletion in late-life depression. J Clin Psychiatry 2018; 79: 16m11371CrossRefGoogle ScholarPubMed
Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984994CrossRefGoogle Scholar
Crossley, NA, Constante, M. Efficacy of atypical v typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196: 434439CrossRefGoogle ScholarPubMed
Crossley, NA, Marques, TR, Taylor, H, et al. Connectomic correlates of response to treatment in first-episode psychosis. Brain 2017; 140: 487496CrossRefGoogle ScholarPubMed
Cummings, JL, Lyketsos, CG, Peskind, ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. J Am Med Assoc 2015; 314: 12421254CrossRefGoogle ScholarPubMed
Cutler, AJ, Montgomery, SA, Feifel, D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70: 526539CrossRefGoogle ScholarPubMed
Czerwensky, F, Leucht, S, Steimer, W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 2013; 16: 21032109CrossRefGoogle ScholarPubMed
Czobor, P, Volavka, J, Meibach, RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243249CrossRefGoogle Scholar
D’Abreu, A, Friedman, JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent. Literature review. Tremor Other Hyperkinet Mov (NY) 2018; 8: 570CrossRefGoogle ScholarPubMed
Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacol 2005; 30: 205211CrossRefGoogle ScholarPubMed
Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012; 43: 303312CrossRefGoogle ScholarPubMed
Dager, SR, Khan, A, Cowley, DS, et al. Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacol Bull 1990; 26: 273278.Google ScholarPubMed
Daly, C, Griffin, E, Ashcroft, DM, et al. Intentional drug overdose involving pregabalin and gabapentin: findings from the National Self-Harm Registry Ireland, 2007–2015. Clin Drug Investig 2018a; 38: 373380CrossRefGoogle Scholar
Daly, J, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2018b; 75: 139148CrossRefGoogle ScholarPubMed
Daly, J, Trivedi, MH, Janik, A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention of patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019; 76: 893903CrossRefGoogle ScholarPubMed
Daniel, DG, Zimbroff, DL, Potkin, SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491505CrossRefGoogle ScholarPubMed
Dannlowski, U, Baune, BT, Böckemann, I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol 2008; 23: 587593CrossRefGoogle ScholarPubMed
Daray, FM, Thommi, SB, Ghaemi, SN. The pharmacogenetics of antidepressant-induced mania: a systemic review and meta-analysis. Bipolar Disord 2010; 12: 702706CrossRefGoogle Scholar
Darbinyan, V, Aslanyan, G, Amroyan, E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61: 343348CrossRefGoogle ScholarPubMed
Davanzano, R, Dal Bo, S, Bua, J, et al. Antiepileptic drug and breastfeeding. Ital J Pediatr 2013; 39: 50CrossRefGoogle Scholar
Davidson, J, Baldwin, D, Stein, DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006; 63: 11581165CrossRefGoogle ScholarPubMed
Davidson, J, Pearlstein, T, Londborg, P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001a; 158: 19741981CrossRefGoogle ScholarPubMed
Davidson, J, Stein, DJ, Rothbaum, BO, et al. Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. J Psychopharmacol 2012; 26: 778783CrossRefGoogle ScholarPubMed
Davidson, JR, Book, SW, Colket, JT, et al. Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 1997a; 27: 153160CrossRefGoogle ScholarPubMed
Davidson, JR, Malik, ML, Sutherland, SN. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol 1997b; 12: 291296CrossRefGoogle ScholarPubMed
Davidson, JR, Potts, N, Richichi, E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13: 423428CrossRefGoogle ScholarPubMed
Davidson, JR, Potts, NL, Richichi, EA, et al. The Brief Social Phobia Scale. J Clin Psychiatry 1991; (52 Suppl): 48S51SGoogle ScholarPubMed
Davidson, JR, Rothbaum, BO, van der Kolk, BA et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001b; 58: 485492CrossRefGoogle ScholarPubMed
Davidson, M, Emsley, R, Kramer, M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93: 117130CrossRefGoogle ScholarPubMed
Davis, JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974; 11: 6569CrossRefGoogle ScholarPubMed
Davis, LL, Barotlucci, A, Petty, F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259266CrossRefGoogle ScholarPubMed
Davis, LL, Davidson, JR, Ward, LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008a; 28: 8488CrossRefGoogle Scholar
Davis, LL, Ota, A, Perry, P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav 2016; 6: e00520CrossRefGoogle ScholarPubMed
Davis, LL, Ward, C, Rasmussen, C, et al. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008b; 41: 818Google ScholarPubMed
Davison, JM, Dunlop, W. Renal hemodynamics and tubular function in normal human pregnancy. Kidney Int 1980; 18: 152161CrossRefGoogle ScholarPubMed
de Bejczy, A, Söderpalm, B. The effects of mirtazapine versus placebo on alcohol consumption in male high consumers of alcohol: a randomized, controlled trial. J Clin Psychopharmacol 2015; 35: 4350CrossRefGoogle ScholarPubMed
Debonnel, G, Saint-André, E, Hébert, C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007; 10: 5161CrossRefGoogle ScholarPubMed
De Hert, M, Sermon, J, Geerts, P, et al. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015; 29: 637658CrossRefGoogle ScholarPubMed
DeKosky, ST, Williamson, JD, Fitzpatrick, AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. J Am Med Assoc 2008; 300: 22532262CrossRefGoogle ScholarPubMed
de la Fuente, JM, Lotstra, F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4: 479486CrossRefGoogle ScholarPubMed
de Leon, J, Wynn, G, Sandson, NB. The pharmacokinetics of risperidone versus paliperidone. Psychosomatics 2010; 51: 8088CrossRefGoogle ScholarPubMed
de Lucena, D, Fernandes, BS, Berk, M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 14161423CrossRefGoogle ScholarPubMed
DeMartinis, A, Schweizer, E, Rickels, K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996; 57: 245248Google ScholarPubMed
Deng, L, Sun, X, Qiu, S, et al. Interventions for management of post-stroke depression: a Bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep 2017; 7: 16466CrossRefGoogle ScholarPubMed
Dennis, CL, Ross, LE, Herxheimer, A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev 2008;(4):CD001690Google ScholarPubMed
de Oliveira, IR, de Sena, EP, Pereira, EL, et al. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther 1996; 21: 229236CrossRefGoogle ScholarPubMed
DePetris, AE, Cook, BL. Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups. Psychiatr Serv 2013; 64: 466471CrossRefGoogle ScholarPubMed
De Picker, L, Van Den Eede, F, Dumont, G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 2014; 55: 536537CrossRefGoogle ScholarPubMed
Depping, AM, Komossa, K, Kissling, W, Leucht, S. Second generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; (12): CD008120Google ScholarPubMed
de Silva, VA, Suraweera, C, Ratnatuga, SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016; 16: 341CrossRefGoogle ScholarPubMed
de Vries, C, van Bergen, A, Regeer, EJ, et al. The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness. Bipolar Disord 2013; 15: 645649CrossRefGoogle ScholarPubMed
Devulapalli, KK, Nasrallah, HA. An analysis of the high psychotropic off-label use in psychiatric disorders. The majority of psychiatric diagnoses have no approved drug. Asian J Psychiatry 2009; 2: 2936CrossRefGoogle ScholarPubMed
DeYoung, CG, Hirsh, JB, Shane, MS, et al. Testing predictions from personality neuroscience: brain structure and the big five. Psychol Sci 2010; 21: 820828CrossRefGoogle ScholarPubMed
Di Florio, A, Forty, L, Gordon-Smith, K, et al. Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry 2013; 70: 168175CrossRefGoogle ScholarPubMed
DiMascio, A, Bernardo, DL, Greenblatt, DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599602CrossRefGoogle ScholarPubMed
Dinz, JB, Shavitt, RG, Fossaluza, V, et al. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 2011; 31: 763768CrossRefGoogle Scholar
Docherty, JP, Sack, DA, Roffman, M, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract 2005; 11: 302314CrossRefGoogle ScholarPubMed
Dodd, S, Dean, OM, Berk, M. A review of the theoretical and biological understanding of the nocebo and placebo phenomena. Clin Ther 2017; 39: 469476CrossRefGoogle ScholarPubMed
Dodd, S, Berk, M, Kelin, K, et al. Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder. J Affect Disord 2013; 150: 344349CrossRefGoogle Scholar
Dodd, S, Schacht, A, Kelin, K, et al. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry 2015; 76: 702711CrossRefGoogle ScholarPubMed
Dodd, S, Walker, AJ, Brnabic, JM, et al. Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder. Bipolar Disord 2019; 21: 142150CrossRefGoogle ScholarPubMed
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neurpharmacol 2015a; 18: pyv047Google ScholarPubMed
Dold, M, Bartova, L, Rupprecht, R, et al. Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials. Psychother Psychosom 2017; 86: 283291CrossRefGoogle ScholarPubMed
Dold, M, Fugger, G, Aigner, M, et al. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 2015b; 166: 187193CrossRefGoogle ScholarPubMed
Dold, M, Li, C, Tardy, M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2012; (11): CD006391Google Scholar
Domes, G, Ower, N, von Dawans, B, et al. Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial. Transl Psychiatry 2019; 9: 328CrossRefGoogle ScholarPubMed
Doody, RS, Ferris, SH, Salloway, S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72: 15551561CrossRefGoogle ScholarPubMed
Dorph-Petersen, KA, Pierri, JN, Perel, JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacol 2005; 30: 16491661CrossRefGoogle ScholarPubMed
Downing, AM, Kinon, BJ, Millen, BA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry 2014; 14: 351CrossRefGoogle ScholarPubMed
Drevets, WC, Zarate, CA Jr., Furey, ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 2013; 73: 11561163CrossRefGoogle ScholarPubMed
Duffy, A, Heffer, N, Goodday, SM, et al. Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: a systematic review: a report from the ISBD-IGSLi joint task force on lithium treatment. Bipolar Disord 2018; 20: 583593CrossRefGoogle ScholarPubMed
Duggal, HS, Mendhekar, DN. High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry 2006; 67: 674675CrossRefGoogle ScholarPubMed
Duinkerke, SJ, Botter, PA, Jansen, AA, et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 1993; 163: 451455CrossRefGoogle ScholarPubMed
Dumon, JP, Catteau, J, Lanvin, F, et al. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149: 647650Google ScholarPubMed
Dumville, JC, Miles, JN, Porthouse, J, et al. Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women. J Nutr Health Aging 2006; 10: 151153Google Scholar
Duncan, EJ, Szilagyi, S, Schwartz, MP, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239248CrossRefGoogle Scholar
Dunkley, EJ, Isbister, GK, Sibbritt, D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635642CrossRefGoogle ScholarPubMed
Dunlop, BW, Kelley, ME, Aponte-Rivera, V, et al. Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Am J Psychiatry 2017; 174: 546556CrossRefGoogle ScholarPubMed
Dunner, DL, Fieve, RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229233CrossRefGoogle ScholarPubMed
Dunner, DL, Amsterdam, JD, Shelton, RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68: 10711077CrossRefGoogle ScholarPubMed
Dupuis, B, Catteau, J, Dumon, JP, et al. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 802805Google ScholarPubMed
Durgam, S, Earley, W, Guo, H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016a; 77: 371378CrossRefGoogle ScholarPubMed
Durgam, S, Earley, W, Li, R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res 2016b; 176: 264271CrossRefGoogle ScholarPubMed
Durgam, S, Gommoll, C, Forero, G, et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial. J Clin Psychiatry 2016c; 77: 16871694CrossRefGoogle ScholarPubMed
Durgam, S, Satlin, A, Vanover, K, et al. Lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized clinical trial. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology, Orlando, Florida, December 8–11, 2019Google Scholar
Durgam, S, Starace, A, Li, D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015; 17: 6375CrossRefGoogle ScholarPubMed
Earley, W, Burgess, MV, Rekeda, L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry 2019a; 176: 439448CrossRefGoogle ScholarPubMed
Earley, WR, Burgess, MV, Khan, B, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020; 22: 372384CrossRefGoogle ScholarPubMed
Earley, W, Guo, H, Daniel, D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res 2019b; 204; 282288CrossRefGoogle ScholarPubMed
Earley, WR, Guo, H, Németh, G, et al. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 2018; 48: 6280Google ScholarPubMed
Egbe, A, Uppu, S, Lee, S, et al. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. Pediatr Neonatol 2015; 56: 2530CrossRefGoogle ScholarPubMed
Eison, AS, Mullins, UL. Regulation of central 5HT2A receptors: a review of in vivo studies. Behav Brain Res 1996; 73: 177181CrossRefGoogle Scholar
Ekeberg, O, Kjeldsen, SE, Greenwood, DT, et al. Effects of selective beta-adrenoceptor blockade on anxiety associated with flight phobia. J Psychopharmacol 1990; 4: 3541CrossRefGoogle ScholarPubMed
el-Ganzouri, AR, Ivankovich, AD, Braverman, B, et al. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg 1985; 64: 592596CrossRefGoogle ScholarPubMed
Elkashef, A, Kahn, R, Yu, E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 2012; 107: 12971306CrossRefGoogle ScholarPubMed
El-Khalili, N, Joyce, M, Atkinson, S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917932CrossRefGoogle ScholarPubMed
El-Mallakh, RS, Vöhringer, PA, Ostacher, MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J Affect Disord 2015; 184: 318321CrossRefGoogle ScholarPubMed
Emamzadehfard, S, Kamaloo, A, Paydary, K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 2016; 70: 332341CrossRefGoogle ScholarPubMed
Erland, LAE, Saxena, PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med 2017; 13: 275281CrossRefGoogle ScholarPubMed
Ernst, CL, Goldberg, JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63(Suppl 4): 4255Google ScholarPubMed
Etkin, A, Patenaude, B, Song, YJ, et al. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology 2015; 40: 13321342CrossRefGoogle ScholarPubMed
Etminan, M, Sodhi, M, Procyshyn, RM, et al. Risk of hair loss with different antidepressants: a comparative retrospective cohort study. Int Clin Psychopharmacol 2018; 33: 4448CrossRefGoogle ScholarPubMed
Faedda, GL, Tondo, L, Baldessarini, RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448455CrossRefGoogle ScholarPubMed
Fallon, BA. Pharmacotherapy of somatoform disorders. J Psychosom Res 2004; 56: 455460CrossRefGoogle ScholarPubMed
Fang, H, Zhen, YF, Liu, XY, et al. Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls. Int Clin Psychopharmacol 2016; 31: 353357CrossRefGoogle ScholarPubMed
Faridhossinie, F, Sadeghi, R, Farid, L, et al. Celecoxib: a new augmentation strategy for depressive mood episodes: a systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29: 216223CrossRefGoogle Scholar
Farnia, V, Gharebaghi, H, Alikhani, M, et al. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial. J Psychiatr Res 2018; 104: 137143CrossRefGoogle ScholarPubMed
Farren, CK, Scimeca, M, Wu, R, et al. Double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend 2009; 99: 317321CrossRefGoogle ScholarPubMed
Fava, M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl 11): 3741Google ScholarPubMed
Fava, M, Rosenbaum, JF. Anger attacks in depression. Depress Anxiety 1998; 8(Suppl 1): 59633.0.CO;2-Y>CrossRefGoogle ScholarPubMed
Fava, GA, Benasi, G, Lucente, M, et al. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 2018a; 87: 195203CrossRefGoogle ScholarPubMed
Fava, GA, Gatti, A, Belaise, C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 7281CrossRefGoogle ScholarPubMed
Fava, M, Durgam, S, Earley, W, et al. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2018b; 33: 312321CrossRefGoogle ScholarPubMed
Fava, M, Evins, AE, Dorer, DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115127CrossRefGoogle Scholar
Fava, M, Ménard, F, Davidsen, CK, et al. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry 2016; 77: 16951701CrossRefGoogle Scholar
Fava, M, Mischoulon, D, Iosifescu, D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81: 8797CrossRefGoogle Scholar
Fava, M, Nierenberg, AA, Quitkin, FM, et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997; 33: 101103Google Scholar
Fava, M, Rappe, SM, Pava, JA, et al. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995; 56: 5255Google ScholarPubMed
Fava, M, Rush, AJ, Alpert, JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165: 342351CrossRefGoogle ScholarPubMed
Fawcett, J, Barkin, RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998; 59: 123127CrossRefGoogle ScholarPubMed
Fawcett, J, Marcus, RN, Anton, SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 (Suppl 6): 3742Google ScholarPubMed
Fawcett, J, Rush, AJ, Vukelich, J, et al. Clinical experience with high-dose pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar disorder. Am J Psychiatry 2016; 173: 107111CrossRefGoogle Scholar
Feder, A, Parides, MK, Murrough, JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71: 681688CrossRefGoogle ScholarPubMed
Fedgchin, M, Trivedi, M, Daly, EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 2019; 22: 616630CrossRefGoogle Scholar
Fein, S, Paz, V, Rao, N, et al. The combination of lithium carbonate and an MAOI in refractory depressions. Am J Psychiatry 1988; 145: 249250Google Scholar
Feinberg, SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry 2004; 65: 15201524CrossRefGoogle ScholarPubMed
Feltner, DE, Crockatt, JG, Dubovsky, SJ, et al. A randomized, double blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240249CrossRefGoogle ScholarPubMed
Feltner, DE, Liu-Dumaw, M, Schweizer, E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26: 213220CrossRefGoogle ScholarPubMed
Ferreria-Garcia, R, da Rocha Freire, RC, Appolinário, JC, et al. Tranylcypromine plus amitriptyline for electroconvulsive therapy-resistant depression: a long-term study. J Clin Psychopharmacol 2018; 38: 502504CrossRefGoogle Scholar
Ferrando, SJ. Psychopharmacologic treatment of patients with HIV/AIDS. Curr Psychiatry Rep 2009; 11: 235242CrossRefGoogle ScholarPubMed
Ferrnadon, SJ, Freyberg, Z. Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry 2008; 20: 6171Google Scholar
Fesler, FA. Valproate in combat-related post-traumatic stress disorder. J Clin Psychiatry 1991; 52: 361364Google Scholar
Fiedorowicz, JG, Endicott, J, Leon, AC, et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011; 168: 4048CrossRefGoogle ScholarPubMed
Figueroa, Y, Rosenberg, DR, Birmaher, B, et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8: 6167CrossRefGoogle ScholarPubMed
Findling, RL, Ginsberg, LD. The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 2014; 10: 15891597CrossRefGoogle ScholarPubMed
Findling, RL, Chang, K, Robb, A, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 2015; 54: 10201031CrossRefGoogle ScholarPubMed
Florio, V, Porcelli, S, Saria, A, et al. Escitalopram plasma levels and antidepressant response. Eur Neuropsychopharmacol 2017; 27: 940944CrossRefGoogle ScholarPubMed
Focosi, D, Azzarà, A, Kast, RE, et al. Lithium and hematology: established and proposed uses. J Leukoc Biol 2009; 85: 2028CrossRefGoogle ScholarPubMed
Foglia, JP, Pollock, BG, Kirschner, MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997; 33: 109112Google ScholarPubMed
Ford, AC, Lacy, BE, Harris, LA, et al. Antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019; 114: 2139CrossRefGoogle ScholarPubMed
Forester, BP, Harper, DG, Georgakas, J, et al. Antidepressant effects with open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol 2015; 35: 338340CrossRefGoogle ScholarPubMed
Förg, A, Hein, J, Volkmar, K, et al. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol 2012; 47: 149155CrossRefGoogle ScholarPubMed
Fornaro, M, Anastasia, A, Novello, S, et al. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord 2018; 20: 195227CrossRefGoogle ScholarPubMed
Förster, K, Jörgens, S, Air, TM, et al. The relationship between social cognition and executive function in major depressive disorder in high-functioning adolescents and young adults. Psychiatr Res 2018; 263: 139146CrossRefGoogle ScholarPubMed
Fournier, JC, DeRubeis, RJ, Hollon, SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc 2010; 303: 4753CrossRefGoogle ScholarPubMed
Franchini, L, Serretti, A, Gasperini, M, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 244259CrossRefGoogle ScholarPubMed
Frank, C. Pharmacologic treatment of depression in the elderly. Can Fam Physician 2014; 60: 121126Google ScholarPubMed
Frank, J. Managing hypertension using combination therapy. Am Fam Physician 2008; 77: 12791286Google ScholarPubMed
Frank, E, Prien, RF, Jarrett, RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851855CrossRefGoogle Scholar
Frankenburg, FR, Zanarini, MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442446CrossRefGoogle ScholarPubMed
Freeman, D, Dunn, G, Murray, RM, et al. How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull 2015; 41: 391399CrossRefGoogle ScholarPubMed
Freeman, EW, Rickels, K, Arredondo, R, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19: 38CrossRefGoogle ScholarPubMed
Freudenreich, O, Goff, DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323330CrossRefGoogle ScholarPubMed
Frieder, A, Fersh, M, Hainline, R, et al. Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs 2019; 33: 265282CrossRefGoogle ScholarPubMed
Friedman, RA, Mitchell, J, Kocsis, JH. Retreatment for relapse following desipramine discontinuation in dysthymia. Am J Psychiatry 1995; 152: 926928Google ScholarPubMed
Friedman, MJ, Marmar, CR, Baker, DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007; 68: 711720CrossRefGoogle Scholar
Frye, MA, Helleman, G, McElroy, SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166: 164172CrossRefGoogle ScholarPubMed
Frye, MA, Ketter, TA, Kimbrell, TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607614CrossRefGoogle ScholarPubMed
Fujii, H, Goel, A, Bernard, N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013; 80: 15651570CrossRefGoogle ScholarPubMed
Furieri, FA, Nakamura-Palacios, EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 16911700CrossRefGoogle ScholarPubMed
Furmark, T, Appel, L, Henningssohn, S, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 2008; 28: 1306613074CrossRefGoogle ScholarPubMed
Furu, K, Kieler, H, Haglund, B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. Br Med J 2015; 350: h1798CrossRefGoogle ScholarPubMed
Furukawa, TA, Cipriani, A, Atkinson, LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled trials. Lancet 2016; 3: 10591066Google Scholar
Furukawa, TA, Cipriani, A, Leucht, S, et al. Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evid Based Ment Health 2018a; 21: 13CrossRefGoogle ScholarPubMed
Furukawa, TA, Levine, SZ, Tanaka, S, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72: 1421CrossRefGoogle ScholarPubMed
Furukawa, TA, Maruo, K, Noma, H, et al. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018b; 137: 450458CrossRefGoogle ScholarPubMed
Fusar-Poli, P, Cappucciati, M, Rutigiano, G, et al. Diagnostic stability of ICD/DSM first episode psychosis diagnoses: meta-analysis. Schizophr Bull 2016; 42: 13951406CrossRefGoogle ScholarPubMed
Fusar-Poli, P, Papanasatiou, E, Stahl, D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015; 41: 892899CrossRefGoogle ScholarPubMed
Gadde, KM, Kopping, MF, Wagner, HT 2nd, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012; 172: 15571564CrossRefGoogle ScholarPubMed
Gallagher, P, Young, AH. Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications. Neuropsychiatr Dis Treat 2006; 2: 3342Google ScholarPubMed
Galling, B, Roldán, A, Hagi, K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 7789CrossRefGoogle ScholarPubMed
Galling, B, Vernon, JA, Pagsberg, AK, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 2018; 137: 187205CrossRefGoogle ScholarPubMed
Gambi, F, De Berardis, D, Campanella, D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005; 19: 483487CrossRefGoogle ScholarPubMed
Garakani, A, Martinez, JM, Marcus, S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008; 23: 269275CrossRefGoogle ScholarPubMed